{'fraction_non_alphanumeric': 0.03146374829001368, 'fraction_numerical': 0.0027359781121751026, 'mean_word_length': 6.393939393939394, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Future Therapy of Cholangiocarcinoma

Bitzer: In early cholangiocarcinoma, operability is the most important issue. Despite low 5-year survival rates even in completely resected tumors (R0 resection), surgery is currently the only possibility to cure the disease. All patients are discussed in an interdisciplinary tumor board, based on magnetic resonance imaging or computed tomography scanning and, if necessary, endoscopic retrograde cholangiopancreatography (ERCP) as an additional investigation, depending on tumor localization, performance status, and laboratory values. In selected patients, fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning can contribute additional important details to the tumor staging.